Clinician opinions on starting treatment for opportunistic infection prevention in interstitial lung disease: the STOP-ILD study.

Immunosuppression for interstitial lung disease carries risk of Pneumocystis pneumonia (PCP). Most surveyed specialists would consider prophylaxis if there is a history of PCP or when commencing cyclophosphamide. Other contexts are contentious. https://bit.ly/3YlVosd.